The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s showing significant potential in clinical trials for addressing obesity. Unlike some available weight loss solutions, retatrutide appears to offer a more substantial loss in body mass and improve metabolic function, particu